Targeting lysyl oxidase (LOX) overcomes chemotherapy resistance in triple negative breast cancer
The development of chemoresistance is a major hurdle in triple negative breast cancer (TNBC). Here, the authors show that lysyl oxidase (LOX) is overexpressed in chemoresistant TNBCs, and when inhibited reduces collagen cross-linking, fibronectin fibril assembly, and downstream integrin signalling,...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2020-05-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/s41467-020-16199-4 |
| _version_ | 1818684382951505920 |
|---|---|
| author | Ozge Saatci Aysegul Kaymak Umar Raza Pelin G. Ersan Ozge Akbulut Carolyn E. Banister Vitali Sikirzhytski Unal Metin Tokat Gamze Aykut Suhail A. Ansari Hayriye Tatli Dogan Mehmet Dogan Pouria Jandaghi Aynur Isik Fatma Gundogdu Kemal Kosemehmetoglu Omer Dizdar Sercan Aksoy Aytekin Akyol Aysegul Uner Phillip J. Buckhaults Yasser Riazalhosseini Ozgur Sahin |
| author_facet | Ozge Saatci Aysegul Kaymak Umar Raza Pelin G. Ersan Ozge Akbulut Carolyn E. Banister Vitali Sikirzhytski Unal Metin Tokat Gamze Aykut Suhail A. Ansari Hayriye Tatli Dogan Mehmet Dogan Pouria Jandaghi Aynur Isik Fatma Gundogdu Kemal Kosemehmetoglu Omer Dizdar Sercan Aksoy Aytekin Akyol Aysegul Uner Phillip J. Buckhaults Yasser Riazalhosseini Ozgur Sahin |
| author_sort | Ozge Saatci |
| collection | DOAJ |
| description | The development of chemoresistance is a major hurdle in triple negative breast cancer (TNBC). Here, the authors show that lysyl oxidase (LOX) is overexpressed in chemoresistant TNBCs, and when inhibited reduces collagen cross-linking, fibronectin fibril assembly, and downstream integrin signalling, overcoming resistance. |
| first_indexed | 2024-12-17T10:49:45Z |
| format | Article |
| id | doaj.art-f292a5a9fd8f4954a8c5c7cfe015c25d |
| institution | Directory Open Access Journal |
| issn | 2041-1723 |
| language | English |
| last_indexed | 2024-12-17T10:49:45Z |
| publishDate | 2020-05-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Nature Communications |
| spelling | doaj.art-f292a5a9fd8f4954a8c5c7cfe015c25d2022-12-21T21:52:02ZengNature PortfolioNature Communications2041-17232020-05-0111111710.1038/s41467-020-16199-4Targeting lysyl oxidase (LOX) overcomes chemotherapy resistance in triple negative breast cancerOzge Saatci0Aysegul Kaymak1Umar Raza2Pelin G. Ersan3Ozge Akbulut4Carolyn E. Banister5Vitali Sikirzhytski6Unal Metin Tokat7Gamze Aykut8Suhail A. Ansari9Hayriye Tatli Dogan10Mehmet Dogan11Pouria Jandaghi12Aynur Isik13Fatma Gundogdu14Kemal Kosemehmetoglu15Omer Dizdar16Sercan Aksoy17Aytekin Akyol18Aysegul Uner19Phillip J. Buckhaults20Yasser Riazalhosseini21Ozgur Sahin22Department of Drug Discovery and Biomedical Sciences, University of South CarolinaDepartment of Drug Discovery and Biomedical Sciences, University of South CarolinaFaculty of Science, Department of Molecular Biology and Genetics, Bilkent UniversityFaculty of Science, Department of Molecular Biology and Genetics, Bilkent UniversityFaculty of Science, Department of Molecular Biology and Genetics, Bilkent UniversityDepartment of Drug Discovery and Biomedical Sciences, University of South CarolinaDepartment of Drug Discovery and Biomedical Sciences, University of South CarolinaFaculty of Science, Department of Molecular Biology and Genetics, Bilkent UniversityFaculty of Science, Department of Molecular Biology and Genetics, Bilkent UniversityFaculty of Science, Department of Molecular Biology and Genetics, Bilkent UniversityDepartment of Medical Pathology, Ankara Yildirim Beyazit UniversityDepartment of Medical Pathology, Ankara Oncology Education and Research HospitalDepartment of Human Genetics, McGill UniversityHacettepe University Transgenic Animal Technologies Research and Application CenterFaculty of Medicine, Department of Pathology, Hacettepe UniversityFaculty of Medicine, Department of Pathology, Hacettepe UniversityDepartment of Medical Oncology, Hacettepe University Cancer InstituteDepartment of Medical Oncology, Hacettepe University Cancer InstituteHacettepe University Transgenic Animal Technologies Research and Application CenterFaculty of Medicine, Department of Pathology, Hacettepe UniversityDepartment of Drug Discovery and Biomedical Sciences, University of South CarolinaDepartment of Human Genetics, McGill UniversityDepartment of Drug Discovery and Biomedical Sciences, University of South CarolinaThe development of chemoresistance is a major hurdle in triple negative breast cancer (TNBC). Here, the authors show that lysyl oxidase (LOX) is overexpressed in chemoresistant TNBCs, and when inhibited reduces collagen cross-linking, fibronectin fibril assembly, and downstream integrin signalling, overcoming resistance.https://doi.org/10.1038/s41467-020-16199-4 |
| spellingShingle | Ozge Saatci Aysegul Kaymak Umar Raza Pelin G. Ersan Ozge Akbulut Carolyn E. Banister Vitali Sikirzhytski Unal Metin Tokat Gamze Aykut Suhail A. Ansari Hayriye Tatli Dogan Mehmet Dogan Pouria Jandaghi Aynur Isik Fatma Gundogdu Kemal Kosemehmetoglu Omer Dizdar Sercan Aksoy Aytekin Akyol Aysegul Uner Phillip J. Buckhaults Yasser Riazalhosseini Ozgur Sahin Targeting lysyl oxidase (LOX) overcomes chemotherapy resistance in triple negative breast cancer Nature Communications |
| title | Targeting lysyl oxidase (LOX) overcomes chemotherapy resistance in triple negative breast cancer |
| title_full | Targeting lysyl oxidase (LOX) overcomes chemotherapy resistance in triple negative breast cancer |
| title_fullStr | Targeting lysyl oxidase (LOX) overcomes chemotherapy resistance in triple negative breast cancer |
| title_full_unstemmed | Targeting lysyl oxidase (LOX) overcomes chemotherapy resistance in triple negative breast cancer |
| title_short | Targeting lysyl oxidase (LOX) overcomes chemotherapy resistance in triple negative breast cancer |
| title_sort | targeting lysyl oxidase lox overcomes chemotherapy resistance in triple negative breast cancer |
| url | https://doi.org/10.1038/s41467-020-16199-4 |
| work_keys_str_mv | AT ozgesaatci targetinglysyloxidaseloxovercomeschemotherapyresistanceintriplenegativebreastcancer AT aysegulkaymak targetinglysyloxidaseloxovercomeschemotherapyresistanceintriplenegativebreastcancer AT umarraza targetinglysyloxidaseloxovercomeschemotherapyresistanceintriplenegativebreastcancer AT pelingersan targetinglysyloxidaseloxovercomeschemotherapyresistanceintriplenegativebreastcancer AT ozgeakbulut targetinglysyloxidaseloxovercomeschemotherapyresistanceintriplenegativebreastcancer AT carolynebanister targetinglysyloxidaseloxovercomeschemotherapyresistanceintriplenegativebreastcancer AT vitalisikirzhytski targetinglysyloxidaseloxovercomeschemotherapyresistanceintriplenegativebreastcancer AT unalmetintokat targetinglysyloxidaseloxovercomeschemotherapyresistanceintriplenegativebreastcancer AT gamzeaykut targetinglysyloxidaseloxovercomeschemotherapyresistanceintriplenegativebreastcancer AT suhailaansari targetinglysyloxidaseloxovercomeschemotherapyresistanceintriplenegativebreastcancer AT hayriyetatlidogan targetinglysyloxidaseloxovercomeschemotherapyresistanceintriplenegativebreastcancer AT mehmetdogan targetinglysyloxidaseloxovercomeschemotherapyresistanceintriplenegativebreastcancer AT pouriajandaghi targetinglysyloxidaseloxovercomeschemotherapyresistanceintriplenegativebreastcancer AT aynurisik targetinglysyloxidaseloxovercomeschemotherapyresistanceintriplenegativebreastcancer AT fatmagundogdu targetinglysyloxidaseloxovercomeschemotherapyresistanceintriplenegativebreastcancer AT kemalkosemehmetoglu targetinglysyloxidaseloxovercomeschemotherapyresistanceintriplenegativebreastcancer AT omerdizdar targetinglysyloxidaseloxovercomeschemotherapyresistanceintriplenegativebreastcancer AT sercanaksoy targetinglysyloxidaseloxovercomeschemotherapyresistanceintriplenegativebreastcancer AT aytekinakyol targetinglysyloxidaseloxovercomeschemotherapyresistanceintriplenegativebreastcancer AT ayseguluner targetinglysyloxidaseloxovercomeschemotherapyresistanceintriplenegativebreastcancer AT phillipjbuckhaults targetinglysyloxidaseloxovercomeschemotherapyresistanceintriplenegativebreastcancer AT yasserriazalhosseini targetinglysyloxidaseloxovercomeschemotherapyresistanceintriplenegativebreastcancer AT ozgursahin targetinglysyloxidaseloxovercomeschemotherapyresistanceintriplenegativebreastcancer |